HARROW 16% INTRADAY DROP CAUGHT!Technical Analysis: HARROW (15-Minute Timeframe)
This chart demonstrates a highly profitable short trade executed with precision using the Risological Indicator. A stellar 16% profit was captured in this intraday trade, showcasing the power of momentum trading.
Trade Details
Stock: HARROW
Timeframe : 15-Minute
Entry Price : $52
Exit Price : $43
Profit : $9 per share (16% intraday return)
Key Technical Observations
Perfect Entry Point:
The entry at $52 aligns with the beginning of a sharp bearish breakout, as identified by the Risological Indicator. The indicator’s red resistance bands provided clear confirmation of a strong downward trend.
Momentum Confirmation:
A steep decline immediately followed the entry, with heavy bearish candles confirming the strength of sellers in the market.
The gap and acceleration downwards signify a likely reaction to negative news or market-wide pressure.
Dynamic Resistance:
The price consistently respected the downward-sloping resistance bands, highlighting the dominance of sellers and a clear absence of bullish recovery attempts.
Exit at $43:
The exit near the $43 level demonstrates disciplined profit-taking, as the stock begins to consolidate and show signs of slowing bearish momentum.
Analysis of Results
This short trade captured the entirety of a massive 16% intraday move, leveraging the indicator’s precise trend-following signals. The sharp entry and timely exit reflect the strength of the Risological Indicator in identifying and capitalizing on market momentum.
Key Takeaways
Trend Confirmation is Critical: The trade capitalized on the established bearish trend, ensuring high probability of success.
Indicator Precision: The Risological Indicator’s dynamic resistance bands provided clear visual cues for both entry and exit, removing guesswork.
Risk Management: By exiting as momentum slowed, the trader avoided potential losses from a reversal or consolidation phase.
This trade underscores the importance of using robust tools like the Risological Indicator to stay ahead in volatile markets, transforming short-term opportunities into substantial profits.
HROW trade ideas
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fundamentals and technicals both align for a sharp move to the upside.
Over the short-term HROW may retest the trend channel breakout around the $17 region. If it holds, which I expect, I believe we could reach a triple-digit share price in short-order, potentially within 18-months, which would be a 500%+ return from today's share price of $19.50.
My personal price target is $150/share by end of year 2025.
Short Term Rise before head and shoulders completion?I see a short term rise in HROW as our current right shoulder of what looks to be a weekly head and shoulders hit a 61.8% Fibonacci retracement level with Stochastic RSI being as oversold as our last oversold areas. I drew two potential rises using some bear rally based Fibonacci Retracments, I feel we will follow the trajectory towards the one that overlaps with the $5.00 Psych Resistance before continuing our decent towards $2.50 to $3.00
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and exchanged no money. In other words, Harrow got off scot-free and will no longer incur legal fees related to the case. This is great news, so it's surprising that the stock is down, especially when the market as a whole is up. Perhaps Harrow will get a boost if some news agencies pick up the story. In the meantime, Harrow is approaching support at about $5. I picked up a few shares at $5.25 and will look to buy more at $5.
Harrow Health has a 9.4/10 Equity StarMine Summary Score and is rated undervalued (73/100) by S&P Capital IQ.